Systemic Inflammation-Based Biomarkers and Survival in HIV-Positive Subject with Solid Cancer in an Italian Multicenter Study

Journal of Acquired Immune Deficiency Syndromes

Volumn 69, Issue 5, 2015, Pages 585-592

  Raffetti, Elena ^a   Donato, Francesco ^a   Pezzoli, Chiara ^a   Digiambenedetto, Simona ^b   Bandera, Alessandra ^c   Di Pietro, Massimo ^d   Di Filippo, Elisa ^e   Maggiolo, Franco ^e   Sighinolfi, Laura ^f   Fornabaio, Chiara ^g   Castelnuovo, Filippo ^h   Ladisa, Nicoletta ⁱ   Castelli, Francesco ^a   Quiros Roldan, Eugenia ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^e Hospital Papa Giovanni XXIII   (Italy)

^f UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^g CREMONA HOSPITAL   (Italy)

^h SPEDALI CIVILI   (Italy)

ⁱ UNIVERSITY OF BARI   (Italy)

Author keywords

cancer; HIV; inflammation based biomarkers; prognostic score; survival

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT TOOL; CLINICAL STUDY; COHORT ANALYSIS; DRUG USE; ELEVATED GLASGOW PROGNOSTIC SCORE; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMEDIATE RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MODIFIED GLASGOW PROGNOSTIC SCORE; MORTALITY; MULTICENTER STUDY; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PLATELET LYMPHOCYTE RATIO; PRIORITY JOURNAL; PROGNOSIS; PROGNOSTIC INDEX; PROGNOSTIC NUTRITIONAL INDEX; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK ASSESSMENT; SOLID TUMOR; BLOOD; CLINICAL TRIAL; COMPLICATION; EPIDEMIOLOGY; ITALY; MIDDLE AGED; NEOPLASM; PATHOLOGY; RISK FACTOR;

ADULT; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; ITALY; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84937792455     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000682     Document Type: Article

References (45)

1. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883-899.
2. O'Callaghan DS, O'Donnell D, O'Connell F, et al. The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol. 2010;5:2024-2036.
3. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009;15:425-430.
4. Jain S, Harris J, Ware J. Platelets: linking hemostasis and cancer. Arterioscler Thromb Vasc Biol. 2010;30:2362-2367.
5. Nieswandt B, Hafner M, Echtenacher B, et al. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999;59: 1295-1300.
6. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454:436-444.
7. Basavaraju U, Shebl FM, Palmer AJ, et al. Cytokine gene polymorphisms, cytokine levels and the risk of colorectal neoplasia in a screened population of Northeast Scotland. Eur J Cancer Prev. 2015;24(4):296-304.
8. Carlsson AC, Juhlin CC, Larsson TE, et al. Soluble tumor necrosis factor receptor 1 (sTNFR1) is associated with increased total mortality due to cancer and cardiovascular causes-findings from two community based cohorts of elderly. Atherosclerosis. 2014;237:236-242.
9. Haller C. Hypoalbuminemia in renal failure: pathogenesis and therapeutic considerations. Kidney Blood Press Res. 2005;28:307-310.
10. Kaysen GA. Biological basis of hypoalbuminemia in ESRD. J Am Soc Nephrol. 1998;9:2368-2376.
11. Proctor MJ, Morrison DS, Talwar D, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer. 2011;104: 726-734.
12. Garcea G, Ladwa N, Neal CP, et al. Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. World J Surg. 2011;35:868-872.
13. Wang DS, Luo HY, Qiu MZ, et al. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol. 2012;29:3092-3100.
14. Smith RA, Bosonnet L, Raraty M, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009;197:466-472.
15. Proctor MJ, Horgan PG, Tawar D, et al. Optimization of the systemic inflammation-based Glasgow prognostic score. Cancer. 2013;119:2325-2332.
16. Templeton AJ, McNamara MG, Seruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124.
17. Yamamura K, Sugimoto H, Kanda M, et al. Comparison of inflammation-based prognostic score as predictors of tumor recurrence in patients with hepatocellular carcinoma after curative resection. J Hepatobiliary Pancreat Sci. 2014;21(9):682-688.
18. Sun K, Chen S, Xu J, et al. The prognostic significance of the prognostic nutritional index in cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2014;140:1537-1549.
19. Wang GY, Yang Y, Li H, et al. A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation. PLoS One. 2011;6:e25295.
20. Kanda M, Fujii T, Kodera Y, et al. Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg. 2011;98:268-274.
21. Templeton AJ, Ace O, McNamara MG, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and metaanalysis. Cancer Epidemiol Biomarkers Prev. 2014;23:1204-1212.
22. Shafique K, Proctor MJ, McMillan DC, et al. The modified Glasgow prognostic score in prostate cancer: result from a retrospective clinical series of 744 patients. BMC Cancer. 2013;13:292.
23. Tenorio AR, Zheng Y, Bosch RJ, et al. Soluble markers of inflammation and coagulation but not t-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014;210:1248-1259.
24. Armah KA, McGinnis K, Baker J, et al. HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis. 2012;55:126-136.
25. Spagnuolo V, Galli L, Salpietro S, et al. Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies. Int J Cancer. 2012;130:2990-2996.
26. Gotti D, Raffeti E, Albini L, et al. Survival in HIV-infected patients after a cancer diagnosis in the cART era: results of an Italian multicenter study. PLoS One. 2014;9:e94768.
27. Worm SW, Bower M, Reiss P, et al. Non-AIDS defining cancers in the D:A:D Study-time trends and predictors of survival: a cohort study. BMC Infect Dis. 2013;13:471.
28. Raffetti E, Albini L, Gotti D, et al. Cancer incidence and mortality for all causes in HIV-Infected patients over a quarter century: a multicentre cohort study. BMC Public Health. 2015;15:235.
29. Marcus JL, Chao C, Leyden WA, et al. Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers. Cancer Epidemiol Biomarkers Prev. 2015. pii: cebp.1079.2014. Epub ahead of print.
30. Kendall CE, Wong J, Taljaard M, et al. A cross-sectional, population-based study measuring comorbidity among people living with HIV in Ontario. BMC Public Health. 2014;14:161.
31. Baranoski AS, Harris A, Michaels D, et al. Relationship between poor physical function, inflammatory markers, and comorbidities in HIV-infected women on antiretroviral therapy. J Womens Health (Larchmt). 2014;23:69-76.
32. World Health Organization. International Classification of Disease (ICD). Available at: http://www.who.int/classifications/icd/en/. Accessed February 23, 2015.
33. Seaman SR, White IR. Review of inverse probability weighting for dealing with missing data. Stat Methods Med Res. 2013;22:278-295.
34. Harrell F. Regression modeling strategies: with applications to linear models, logistic regression and survival analysis. In: Springer Series in Statistics. New York, NY: Springer-Verlag; 2001.
35. Akaike H. A New Look at the Statistical Model Identification. IEEE Trans Autom Control. 1974;19(6):716-723.
36. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
37. Templeton AJ, Pezaro C, Omlin A, et al. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer. 2014;120:3346-52.
38. Hermanns T, Bhindi B, Wei Y, et al. Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Br J Cancer. 2014;111:444-451.
39. Kang MH, Go SI, Song HN, et al. The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer. 2014;111:452-460.
40. Ikeguchi M, Urushibara S, Shimoda R, et al. Inflammation-based prognostic scores and nutritional prognostic index in patients with locally-advanced unresectable colorectal cancer. World J Surg Oncol. 2014;12:210.
41. Jiang N, Deng JY, Ding XW, et al. Prognostic nutritional index predicts postoperative complications and long-term outcomes of gastric cancer. World J Gastroenterol. 2014;20:10537-10544.
42. Tanoglu A, Karagoz E, Yiyit N, et al. Is combination of neutrophil to lymphocyte ratio and platelet lymphocyte ratio a useful predictor of postoperative survival in patients with esophageal squamous cell carcinoma. Onco Targets Ther. 2014;7:433-434.
43. Zhang Y, Wang L, Liu Y, et al. Preoperative neutrophil-lymphocyte ratio before platelet-lymphocyte ratio predicts clinical outcome in patients with cervical cancer treated with initial radical surgery. Int J Gynecol Cancer. 2014;24:1319-1325.
44. Wang D, Wu M, Feng FZ, et al. Pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios do not predict survival in patients with cervical cancer treated with neoadjuvant chemotherapy and radical hysterectomy. Chin Med J. 2013;126:1464-1468.
45. Lages EL, Belo AV, Andrade SP, et al. Analysis of systemic inflammatory response in the carcinogenic process of uterine cervical neoplasia. Biomed Pharmacother. 2011;65:496-499.